2022
DOI: 10.1038/s41589-022-01181-6
|View full text |Cite
|
Sign up to set email alerts
|

Author Correction: Selective inhibitors of JAK1 targeting an isoform-restricted allosteric cysteine

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…Similar to the target‐centric approach, the ligand‐centric approach also requires chemical optimization to improve the potency and selectivity of the fragment hits for the target of interest. In a recent application of ligand‐centric FBDD, Cravatt and coworkers successfully developed novel allosteric modulators of the Janus tyrosine kinase 1 (JAK1) with high potency and unprecedented isoform selectivity within the JAK family, which involved initial screening of a covalent fragment library against the human T‐cell proteome for discovering the fragment hits of JAK1 [48] …”
Section: Approaches For Discovering Covalent Ligandsmentioning
confidence: 99%
See 1 more Smart Citation
“…Similar to the target‐centric approach, the ligand‐centric approach also requires chemical optimization to improve the potency and selectivity of the fragment hits for the target of interest. In a recent application of ligand‐centric FBDD, Cravatt and coworkers successfully developed novel allosteric modulators of the Janus tyrosine kinase 1 (JAK1) with high potency and unprecedented isoform selectivity within the JAK family, which involved initial screening of a covalent fragment library against the human T‐cell proteome for discovering the fragment hits of JAK1 [48] …”
Section: Approaches For Discovering Covalent Ligandsmentioning
confidence: 99%
“…In a recent application of ligand-centric FBDD, Cravatt and coworkers successfully developed novel allosteric modulators of the Janus tyrosine kinase 1 (JAK1) with high potency and unprecedented isoform selectivity within the JAK family, which involved initial screening of a covalent fragment library against the human T-cell proteome for discovering the fragment hits of JAK1. [48] In this review, we present two case studies that involved the application of either the target-centric or the ligand-centric method toward covalent ligand discovery in our laboratory. Employing the target-centric method, we rapidly identified highly potent and specific inhibitors for a receptor tyrosine kinase EphB3.…”
Section: Approaches For Discovering Covalent Ligandsmentioning
confidence: 99%